The scrutiny centers on an August 13, 2026, financial update. While Abeona reported that five patients received treatment with its one-time therapy, prademagene zamikeracel, the company acknowledged that revenue could only be recognized for four of those cases. Management attributed the shortfall to a specific batch of the product that failed to meet the required sheet count for financial recognition.

Following the announcement, shares of the NASDAQ-listed company dropped by $1.12, closing at $6.35. Pomerantz LLP, a firm with a long-standing history in corporate and securities litigation, is now inviting investors to come forward as they evaluate potential breaches of fiduciary duty or unlawful business practices. Investors seeking to participate in the ongoing review are directed to contact Danielle Peyton for further legal guidance.